After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi (Nasdaq: SNY)’s decision to sell its over-the-counter business to a U.S. buyout firm descended into mudslinging, public rebukes and political discord.
To read the entire story, you must be logged in.
Please log in now or register with us.
